Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

MID-TERM REVISION RISK OF PRIMARY MODULAR TOTAL HIP REPLACEMENT STEM FINDINGS FROM THE CANADIAN JOINT REPLACEMENT REGISTRY

Canadian Orthopaedic Association (COA) and Canadian Orthopaedic Research Society (CORS) Annual Meeting, June 2016; PART 1.



Abstract

Modular total hip arthroplasty (MTHA) stems were introduced in order to provide increased intra-operative flexibility for restoring hip biomechanics, improving stability and potentially reducing revision risk. However, the additional interface at the neck-body junction provides another location for corrosion or mechanical failure of the stem. To delineate the mid term revision risk of MTHA stems, we examined data from the Canadian Joint Replacement Registry (CJRR) at the Canadian Institute for Health Information (CIHI).

Kinectiv, Profemur and Rejuvenate modular stems were identified from CJRR records submitted between 2004 and 2014. Revision status was determined by examining the discharge abstract database (DAD) also housed by CIHI, which collects information on all revisions, regardless of whether the procedure was submitted to CJRR.

A total of 2446 modular stems were identified with a mean follow up of 4.2 years (range 0 to 10). Their usage peaked in 2012 (the first year of mandatory CJRR form submission for BC, ON and MB), and dropped rapidly thereafter. A total of 155 (6.3%) were revised. This consisted of 5/301 Kinectiv (1.7%), 141/2050 ProFemur (6.9%), and 9/96 Rejuvenate (9.4%) stems. As a group, this falls below the National Institute for Clinical Excellence (NICE) guidelines of 95% survival at 10 years.

While MTHA stems were introduced to improve outcomes and reduce revision risk, our findings of a 6.3% revision risk at a mean follow up of 4.2 years does not appear to support this.


Email: